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INTRODUCTION
Clinical significance of EGFRvIII in human cancer
Prostate cancer is one of the most commonly diagnosed invasive malignancies and is the second leading cause of death in American men (1) (2) (3) . The epidermal growth factor receptor (EGFR/ErbB) family is a group of tyrosine kinases, frequently overexpressed in a variety of carcinomas (4) (5) (6) . This class I subfamily is comprised of four members: EGFR (4), HER2/p 185erbB-2/neu (5) , HER3/p 160erb 3(6) and HER4/p 180 erbB-4 (19) . Autocrine production of transforming growth factor alpha (TGFa) and overexpression of epidermal growth factor receptor (EGFR) may contribute to androgen-independent prostate cancer growth at both primary and metastatic sites (4) . The epidermal growth factor receptor (EGFR) is a promising target for various anti-neoplastic agents. However, normal EGFR may be targeted by these anti-EGFR agents, a more appropriate strategy might be to target an alteration within the receptor.
Several reports have documented spontaneous rearrangements within the EGF receptor gene in primary human glioblastoma tumor (7) (8) (9) (10) . Three different types of mutants result from these rearrangements (8) . The most common of these rearrangements is the Type III EGF deletionmutant receptor (EGFRvIII), which involves a deletion of exons 2-7, (cDNA nucleotide 275-1075), presumably through alternative splicing or rearrangements (11, 12) . Overexpression of this mutant EGF receptor in NIH3T3 cells results in transformed morphology, enhanced growth, and tumorigenicity in athymic mice (13) .
Crosslinking experiments with EDAC demonstrate that the mutant EGF receptor is dimerized in the absence of ligand. EGFRvIII has not been detected in normal adult tissues. Recent reports demonstrated that the EGFRvIII is also frequently detected in human prostate cancer (12, 14) . Our preliminary results detected 44% of primary prostate cancer specimens express EGFRvIII. All of these EGFRvIII positive tumors appear to be poorly differentiated with high Gleason grade prostatic adenocarcinomas. This phenomenon is the first evidence that EGFRvIII expression is detected in high grade human prostate cancer.
Furthermore, overexpressing EGFRvIII in a murine hematopoietic IL3-dependent cell line (32D cells) caused acquisition of a ligand-independent and IL-3-independent phenotype and formed large tumors in nude mice (21) . However, the tumorigenicity potential of EGFRvIII in prostatic cancer cells has not yet been explored. The understanding of the function and biology of EGFRvIII will have important implications in the prognosis and treatment of prostate cancer.
Ribozymes:
Specific gene modulation, using oligonucleotides, including triplex DNA, antisense DNA/RNA and ribozymes, have been used as strategies for suppressing activated oncogenes (17) (18) (19) (20) . Ribozymes are catalytic RNAs that are capable of specific strand scission (15, 16) . The targeting of specific gene transcripts with ribozyme constructs can successfully inactivate genes produced in cells and can generate dominant negative mutant (15) . Hammerhead ribozymes are self-cleaving RNAs whose catalytic activity has been mapped to a small core of less than 40 nucleotides, arranged in a typical three-stem structure (15, 16) . The targeted cleavage site is GUX (X is either A, U, or C) (15, 16) . Targeted suppression of specific gene expression by ribozymes has been reported (17) , including activated ras and truncated bcr-abl gene (19, 20) . In our previous studies, we generated a specific ribozyme targeting ErbB-4. We demonstrated that ribozyme-mediated down-regulation of ErbB-4 resulted in reduction of proliferation in vitro and inhibition of tumor growth in vivo in breast cancer cell lines (18) . Ribozymes, therefore, provide an alternative way for modulation of specific gene expression. High frequency of EGFRvIII expression is detected in a wide variety of human tumors, but it is not detectable in normal tissues, therefore, it might be an excellent target for biologically based therapies. Our AIM 3 will use ribozyme strategy targeting the novel fusion junction of EGFRvIII in order to block EGFRvIII expression in prostate cancer cells so that we may study the effect on tumor progression. In theory, the EGFRvIII ribozyme should be tumor specific and the ultimate goal of this study is to provide proof of principle for a potential translational gene therapy.
In this final report, I will summarize all our findings that we have accomplished during the last three year funding period. We have achieved the goals that were proposed in the proposal. Results:
Previously, we demonstrated that 44% of prostate cancers express EGFRvlII ( Figure 1 ).
To investigate whether any correlation might exist between the ErbB-2 expression and EGRFvIII expression in prostate cancer, we performed immunohistochemical analysis with a specific ErbB-2 antibody on the same set of prostate cancer tissue microarrays. We detected that about 35%
(74/208) of prostate cancer specimens express both EGFRvIII and ErbB-2. Within this set of 74 prostate cancer samples, about 28% (20/74) of these cases exhibit high expression levels of both EGFRvIII and ErbB-2 receptors. There are 31% (65/208) of these prostate cancer specimens that were negative for both receptors. Other tumors express either EGFRvIII or ErbB-2 alone. Table I summarizes the percentage of co-expression of EGFRvlII and ErbB-2 in prostate cancer patient specimens. Research Products, MA). Immunoreactivity was scored with both the percentage of cells positive and the overall intensity of the staining was taken into account.
2)
Immunoprecipitation . Total cell lysates (30ug) from TSU and TSU/EGFRvIII transfectants were separated by electrophoresis using SDS-PAGE and transferred onto nitrocellulose membranes. Bands were visualized using monoclonal EGFRvIII antibody (4-5H) and a chemiluminescence's detection system.
Constitutively activated EGFRvIII in TSU transfectants
In an effort to better understand the biological role of EGFRvIII in prostate cancer, we further evaluated the autophosphorylation of EGFRvIII by immunoprecipitation with antiEGFRvIII (4-5H) antibody, subsequently western blotting with a specific phosphotyrosine antibody. As shown in Figure 5 , EGFRvIII are constitutively activated in Tsu/EGFRvIII transfectants. Moreover, comparing with the parental cells, expressing EGFRvIII in Tsu cells induces wild-type EGFR phosphorylation. These results suggest that EGFRvIII could activate wild-type EGFR signaling pathways, further indicating that EGFRvIII may heterodimerize with wild-type EGFR and diversify its signaling pathways. . One mg of lysates from various EGFRvIII transfected TSU cells (clone #12 and #16) and the parental TSU cells were immunoprecipitated with a specific anti-EGFR antibody, which recognizes both the wild-type EGFR and the mutant form (EGFRvIII) of EGFR. These precipitated proteins were subsequently subjected to western blotting with an antiphosphotyrosine antibody. Bands were visualized using a chemiluminescence detection system. These results demonstrate that EGFRvIII is constitutively activated in a ligandindependent manner in prostate transfectants. In addition, expressing EGFRvIII enhances wildtype EGFR phosphorylation, which implies that EGFRvIII could activate wild-type EGFR signaling pathways.
EGFRvIII Enhances Prostate Cancer Cell Proliferation.
To evaluate whether overexpression of EGFRvIII will have any effects on prostate cancer cell proliferation, anchorage-dependent growth assays were conducted to assess and correlate the EGFRvIII expression levels with the rate of proliferation. Three independent experiments were performed in triplicate determining cell numbers on day 2, 4, and 7. Values were reported as the mean of triplicate determinations ± SD. 
Expressing EGFRvIII Enhances Tumorigenicity in vivo.
Because expressing EGFRvIII enhances proliferation of prostate cancer cells in vitro, we wondered whether expressing EGFRvIII in prostate cancer cells would be able to increase the malignancy in vivo. We explored the potential tumorigenicity of EGFRvIII in vivo and as we expected, expressing EGFRvIII in prostate cancer cells enhance tumorigenicity in nude mouse as demonstrated in Figure 9 . immunoblotted with anti-phosphotyrosine monoclonal antibody (Upstate, Lake Placid, NY), followed by blots with 0.5 ug/ml of secondary antibody linked to horseradish peroxidase.
Immunoreactive bands were detected with an enhanced chemiluminescence reagent (ECL;
Amersham Corp.).
4) Anchorage-dependent growth assays:
Cells was harvested after trypsin treatment and 5,000 cells/well was plated in 24-well plates (Costar). All samples were prepared in triplicate.
Three independent assays were performed. Cells were counted in a Coulter Counter (Coulter Electronics LTD, Hialeah, FL) on day 2 (the following day), day 4 and day 7. Cell counts will be reported as the means of triplicate determinations ± SD.
5) In vivo study:
We injected intraperitoneal (5 x 106 cells) Tsu/wt, Tsu/EGFRvIII into 4-6 week old male athymic nude mice, using five mice per group. Tumor growth was monitored and the tumor size was measured twice weekly from which we were able to calculate the tumor volume (length x width x thickness).
Specific Aim 3: Generation of tumor-specific ribozyme targeted at the novel fusion junction of EGFRvIII.
Rationale: EGFRvIII is a tumor specific cell surface molecule. A high frequency of EGFRvIII receptor is found in prostate cancers, but is not found in normal prostate tissue (12, 14 
Results: Generation of EGFRvIII ribozyme targeting the fusion junction of EGFRvIII
In an attempt to elucidate whether down-regulation of EGFRvIII in prostate cancer cells would reduce the tumorigenicity. We generated a specific ribozyme targeting the novel junction 1111111 1111111 Figure 10 . Schematic representation of a specific hammer-head ribozyme targeting the novel junction of EGFRvIII mRNA.
Principal Investigator: Careen K. Tang, Ph.D.
EGFRvIII ribozyme-mediated mRNA cleavage in vitro.
To evaluate the catalytic activity of this ribozyme, we first conducted an in vitro run-off transcript to assess the ribozyme-mediated cleavage of EGFRvIII mRNA. As shown in Figure   11 , this ribozyme precisely and efficiently cleaves EGFRvIII mRNA. .ribozyme in a cell free system. Lane 1 
Evaluation of the specificity and effieacy of EGFRvIII ribozyme in an intracellular model system (32D cells):
Although ribozyme sensitivity in an extracellular system can be correlated with the predicted secondary structure of the target RNA, the intracellular susceptibility of the target RNAs to ribozymes does not necessarily correlate with their predicted secondary structure. We evaluated the intracellular EGFRvIII ribozyme efficacy and specificity by utilizing the 32D cell system.
The 32D cell is an IL-3 dependent mouse hematopoetic cell line. We observed that overexpression of EGFRvIII in these cells capable of proliferating in the absence of IL-3 ( Figure   12 ) and addition of exogenous EGF werefurther enhanced their growth ( Figure 12 ). In contrast, the parental 32D cells absolutely required IL-3 for growth and were unresponsive to EGF treatment. The wild-type 32D/EGFR cells required either IL-3 or cognate ligands for EGFR for growth. In the absence of IL-3 or lacking of cognate ligands, 32D/EGFR cells did not survive.
However, high levels of EGFRvIII were able to abrogate these IL-3-dependent pathways in the absence of IL-3 and absence of ligands. As demonstrated in Figure 12 , 32D cells overexpressing EGFRvIII (32D/EGFRvIII P5) were able to survive and proliferate in the absence of IL-3 and in Principal Investigator: Careen K. Tang, Ph.D.
the absence of ligands (21) . Thus, this system provided a simple bio-assay though which ribozyme activity can easily be detected. 100 ng/ml of human recombinant EGF (open bar).
Eo
Viable cells were counted on day 3 after seeding.
samples were prepared in triplicate. This assay was
Cell Lines repeated more than three times.
EGFRvIII-ribozyme mediated downregulation of EGFRvIII in an intracellular model system:
We constructed EGFRvIII-ribzoyme into pcDNA3.1/zeo vector and transfected it into 32D/EGFRvIII cells. The individual clones that are resistant to zeocin were selected and characterized. Northern blotting was performed to determine the EGFRvIII mRNA expression in ribozyme transfected 32D/EGFRvIII cells.
Immunoblotting was performed to confirm the ribozyme-mediated down-regulation of EGFRvIII in the transfected cells, as shown in Figure 13 . The ribozyme was able to efficiently reduce the EGFRvIII expression levels in 32D/EGFRvIII, which suggests that we have generated a biologically activate EGFRvIII ribozyme. Immunoreactive bands were detected with an enhanced chemiluminescence's reagent. Figure 14A . EGFRvIII ribozyme has no effect on wild-type EGFRmRNA. RNA extracted from EGFR cells and ribozyme transfected cells were subjected to northern blotting with an EGFR probe. Lane I is EGFR transfected parental cells. Lane 2 and lane 3 are two ribozyme transfected EGFR expressing clones. 
32D/ EGFR
Characterization of ribozyme transfected 32D/EGFRvIII cells in vitro:
To evaluate whether down-regulation of EGFRvIII will reduce proliferation and reverses the IL-3-independent phenotype. Growth assays were conducted to assess and correlate the EGFRvIII expression levels. Three independent experiments were performed, each in triplicate. Cell number was determined every 2 days, after testing for cell viability by trypan blue exclusion. Values were reported as the mean of triplicate determinations ± SD. We observed that ribozyme transfected 32D/EGFRvIII cells exhibited IL-3-dependent phenotype as shown in Figure 15 . These results suggest that we have generated a biological functional ribozyme, which is capable of downregulating the EGFRvIII protein levels intracellular and restoring the IL-3-dependent phenotype. Reaction products were analyzed on 6% urea polyacrylamide gel and products were detected by autoradiography. A secondary FITC-anti-mouse antibody (CALTAG, CA, USA) was used, and the expression levels of EGFR and EGFRvIII were quantitatively measured by flow cytometry.
3)
5) Evaluation of ribozyme down-regulation of EGFRvIII by Western blotting: Cells
were lysed in HEPES lysis buffer (50 nM HEPES, 150mM NaCI, 10% glycerol, 1% Triton X 100, 1.5 mM MgCl 2 , and 1mM EGTA), and the cell debris was pelleted by centrifugation (7). 
6)
Growth assays: 50,000 cells/well in IL-3 free medium were plated in 24-well plates (Costar), medium supplemented with IL-3, or medium lacking IL-3 but supplemented with I OOng/ml of EGF were used for this assay. All samples were prepared in triplicate. Three independent assays were performed. Cells were counted in a Coulter Counter (Coulter Electronics LTD, Hialeah, FL) on day 2. Cell counts were reported as the means of triplicate determinations ± SD. We also demonstrate that EGFRvIII transfected prostate cancer cells enhance tumorigenicity in vivo.
KEY RESEARCH ACCOMPLISHMENTS
We have generated a tumor-specific ribozyme targeting the fusion junction of EGFRvIIImRNA.
We demonstrate that this ribozyme is capable of cleave the EGFRvIII mRNA precisely and efficiently in a cell free system under the physiological condition.
We also demonstrate that this ribozyme is biological functional. EGFRvIII-ribozyme can efficiently reduce the EGFRvIII expression in an intracellular model system. In contrast, this ribozyme does not have any effects on wild-type EGFR mRNA and protein levels.
Down-regulation of EGFRvIII by ribozyme reverses the IL-3-independent phenotype.
CONCLUSION
We have successfully completed the proposed study and achieved our goal by provide these solid evidences to prove our hypothesis. 
